



## dasatinib 20mg, 50mg, 80mg, 100mg, 140 mg film-coated tablets (Sprycel®)

Bristol-Myers Squibb Pharmaceuticals Ltd

8 March 2019

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**dasatinib (Sprycel®)** is accepted for use within NHSScotland.

**Indication under review:** for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.

SMC has previously accepted dasatinib for use in the treatment of adult patients with newly diagnosed Ph+ CML-CP (SMC No. 1170/16) and Ph+ CML-CP resistant or intolerant to prior therapy including imatinib (SMC No. 370/07).

Dasatinib was accepted for use in the treatment of adult patients with Ph+ CML-CP resistant or intolerant to prior therapy including imatinib (SMC No. 370/07) following a submission under the orphan process.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of dasatinib. This SMC advice is contingent upon the continuing availability of the patient access scheme or a list price that is equivalent or lower.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 07 December 2018.*

**Chairman**  
**Scottish Medicines Consortium**